Intensive Glucose Lowering Reduces Diabetics' Heart Risks
But the regimen may not reduce stroke and all-cause mortality in type 2 diabetics
FRIDAY, May 22 (HealthDay News) -- In patients with type 2 diabetes, an intensive glucose-lowering regimen significantly reduces coronary events without increasing the risk of death, according to a study published in the May 23 issue of The Lancet.
Kausik K. Ray, M.D., of the University of Cambridge in the United Kingdom, and colleagues conducted a meta-analysis of five trials, in which 33,040 participants were randomly assigned to either an intensive glucose-lowering regimen or a standard regimen.
Compared to the standard regimen, the researchers found that the intensive regimen was associated with significant reductions in nonfatal myocardial infarction and coronary heart disease events (odds ratios, 0.83 and 0.85, respectively). However, they found that it did not significantly reduce either stroke or all-cause mortality (odds ratios, 0.93 and 1.02, respectively).
"The optimum methods to achieve glycemic control need to be established, and guidelines drawn up with specific recommendations for reduction of HbA1c concentration in a range of patient populations," the authors conclude.
Two co-authors have received honoraria from various pharmaceutical companies.